What Is an Amylin Receptor Agonist?
An amylin receptor agonist is a drug that switches on the same receptors your own amylin hormone uses. “Agonist” simply means something that activates a receptor, the way the right key turns a lock. When the drug locks on, your body responds as if it had released extra amylin after a meal.
Amylin receptors sit in several places, including parts of the brain that control how much you eat, according to a Cleveland Clinic review of amylin and pramlintide. That is why this drug class mainly affects appetite and fullness rather than burning fat directly.
Drugs in this class come in two styles. Selective agonists act mainly on amylin receptors. Non-selective agonists also act on calcitonin receptors, close relatives of the amylin receptor. Lilly’s discovery paper on eloralintide describes eloralintide as selective and cagrilintide as non-selective. In animal studies, eloralintide caused less nausea-like behavior than cagrilintide, but the two have not been compared head to head in people. Our guide to eloralintide vs cagrilintide covers the differences in detail.
What Is Amylin and What Does It Do?
Amylin is a small hormone, 37 amino acids long, that your pancreas releases at the same time as insulin when you eat. It comes from beta cells, the insulin-making cells in your pancreas, and it works alongside insulin to keep blood sugar steady after meals.
According to the Cleveland Clinic review, amylin has four main jobs:
- Lowers glucagon after meals. Glucagon is a hormone that tells your liver to release stored sugar. Less glucagon means less sugar dumped into your blood after eating.
- Slows stomach emptying. Food leaves your stomach more gradually, so sugar enters your blood more slowly.
- Signals fullness. Amylin acts on the brain to help you feel satisfied with less food.
- Reduces the blood sugar spike after meals. This is the combined result of the three effects above.
People with type 1 and type 2 diabetes make less amylin, and the shortfall tends to match how low their insulin is. Natural amylin is also sticky and unstable as a liquid, so it cannot be used as a medicine on its own. Drugmakers had to change its structure to create usable versions, starting with pramlintide.
How an Amylin Receptor Agonist Works
An amylin receptor agonist works mainly by making you feel full sooner and for longer, so you eat fewer calories. Lilly says eloralintide’s effect on calorie intake is likely driven by satiety, the feeling of fullness, according to its Phase 2 results announcement.
What an Amylin Receptor Agonist Does
| What the drug does | What you may notice |
|---|---|
| Signals fullness in the brain | Smaller portions and feeling satisfied sooner |
| Slows stomach emptying | Food stays with you longer; nausea is possible, especially early on |
| Lowers glucagon after meals | A smaller blood sugar rise after eating |
| Reduces calorie intake over time | Gradual weight loss |
The newer drugs differ from the original in one big way: how long they last. Pramlintide has a short half-life of about 48 minutes and is injected before major meals, according to the SymlinPen prescribing information on DailyMed. Eloralintide and cagrilintide are long-acting and are given once a week in trials.
That change matters for weight loss. In diabetes trials, pramlintide’s weight effect was modest, about 1.8 kg (4 lb) more than placebo in one pooled analysis cited by the Cleveland Clinic review. The weekly drugs have produced much larger losses, which is why the drug class is back in the headlines.
Is an Amylin Agonist the Same as a GLP-1 Drug?
No. An amylin receptor agonist copies a different hormone and acts on a different receptor from GLP-1 drugs. GLP-1 drugs such as semaglutide copy GLP-1, a hormone made in your gut. Tirzepatide acts on two gut hormone receptors, GIP and GLP-1.
Both types reduce appetite and slow the stomach, but through separate pathways. Lilly has said eloralintide could serve as an alternative to these incretin drugs, or be added to them for people who need more weight loss.
Amylin Agonists vs. Other Weight Loss Drug Types
| Drug type | Hormone it copies | Examples | Status (October 2026) |
|---|---|---|---|
| GLP-1 receptor agonist | GLP-1 | Semaglutide (Wegovy, Ozempic) | FDA-approved |
| GIP and GLP-1 receptor agonist | GIP and GLP-1 | Tirzepatide (Zepbound, Mounjaro) | FDA-approved |
| Amylin receptor agonist | Amylin | Pramlintide (Symlin); eloralintide; cagrilintide | Pramlintide approved for diabetes; others investigational |
| Amylin plus GLP-1 combination | Amylin and GLP-1 | CagriSema; EloraTZP (with tirzepatide) | Investigational |
| GIP, GLP-1 and glucagon agonist | Three hormones | Retatrutide | Investigational, not for sale |
Retatrutide often comes up in the same news stories, but it is not an amylin drug. Lilly describes it as an investigational triple receptor agonist that acts on GIP, GLP-1 and glucagon receptors. It is not approved and not for sale. You can read more in our post on what retatrutide is.
Which Amylin Receptor Agonists Are Approved or in Trials?
As of October 28, 2026, only one amylin receptor agonist is FDA-approved, and it is approved for diabetes, not weight loss. Several weekly amylin drugs are in late-stage trials.
Amylin Receptor Agonists: Approved and in Trials
| Drug | Company | How it is given | Where it stands |
|---|---|---|---|
| Pramlintide (Symlin) | AstraZeneca | Injection before major meals | FDA-approved for type 1 and type 2 diabetes in people who use mealtime insulin |
| Eloralintide | Eli Lilly | Once-weekly injection (in trials) | Phase 3 trials ongoing; not approved |
| CagriSema (cagrilintide plus semaglutide) | Novo Nordisk | Once-weekly injection (in trials) | Under FDA review; Novo expects a decision in Q4 2026; not approved |
| EloraTZP (eloralintide plus tirzepatide) | Eli Lilly | Weekly injections (in trials) | Phase 2b complete; Lilly plans to start Phase 3 in Q4 2026 |
CagriSema is the furthest along. In the 68-week REDEFINE 1 trial of cagrilintide and semaglutide, 3,417 adults with overweight or obesity lost an average of 20.4% of their body weight, compared with 3.0% on placebo. Novo Nordisk filed CagriSema with the FDA in December 2025 and, in a September 2026 update, said it still expects a decision in the fourth quarter of 2026. Our roundup of new weight loss drugs covers CagriSema alongside other drugs in development.
EloraTZP pairs eloralintide with tirzepatide. In a 48-week Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, Lilly reported weight loss of up to 23.3% and greater weight and A1C reductions than tirzepatide 15 mg alone, according to its EloraTZP results announcement.
What Eloralintide Trials Have Shown So Far
In its Phase 2 trial, eloralintide led to average weight loss of 9.5% to 20.1% after 48 weeks, depending on the dose, compared with 0.4% on placebo. The study included 263 adults with obesity or overweight plus at least one weight-related health problem, none of whom had type 2 diabetes. Their average starting weight was 240.5 lb. The results were published in The Lancet’s 48-week eloralintide trial report.
Eloralintide Phase 2 Results at 48 Weeks
| Trial group | Average weight loss at 48 weeks | Average pounds lost |
|---|---|---|
| Eloralintide 1 mg | 9.5% | 22.5 lb |
| Eloralintide 3 mg | 12.4% | 29.3 lb |
| Eloralintide 6 mg | 17.6% | 41.2 lb |
| Eloralintide 9 mg | 20.1% | 47.0 lb |
| Stepped up from 6 mg to 9 mg | 19.9% | 46.3 lb |
| Stepped up from 3 mg to 6 mg to 9 mg | 16.4% | 39.2 lb |
| Placebo | 0.4% | 0.4 lb |
Source: Eli Lilly Phase 2 results announcement, efficacy estimand.
The doses above come from a research study and are shown for information only. They are not dosing instructions, and there is no approved dose of eloralintide. Talk to your prescriber about any weight loss medicine before you start, stop or change it.
Lilly also reported improvements in waist size, blood pressure, cholesterol and other blood fats, blood sugar control, and markers of inflammation. The most common side effects were mild to moderate stomach symptoms and fatigue. These were more common at higher doses, less common when the dose was raised slowly, and similar to placebo at 1 mg and 3 mg. Our post on eloralintide side effects breaks these down by dose.
Keep the limits of this evidence in mind. It was one 48-week trial of 263 people, funded by Lilly. Larger Phase 3 trials, which Lilly says are under way, will show whether these results hold up and what longer-term safety looks like.
Are Amylin Receptor Agonists Safe?
Trials so far show that the main side effects of amylin receptor agonists are stomach-related, especially nausea, and that these are usually mild to moderate. Long-term safety for the new weekly drugs is not yet known because their Phase 3 trials are still running or under review.
Here is what the evidence shows for each drug that has data:
- Pramlintide (Symlin): The SymlinPen prescribing information carries a boxed warning for severe low blood sugar when it is used with insulin, especially in type 1 diabetes. When this happens, it occurs within 3 hours of the injection. The label notes that pramlintide alone does not cause low blood sugar.
- CagriSema: In REDEFINE 1, stomach side effects affected 79.6% of people on CagriSema and 39.9% on placebo. They were mostly mild to moderate and short-lived.
- Eloralintide: In the Phase 2 trial, nausea ranged from 11% to 64% across dose groups, compared with 14% on placebo. Fatigue was the other common side effect.
Eloralintide and cagrilintide are not approved medicines. Products sold online under these names, including vials labeled “for research use only,” are not FDA-approved drugs, and there is no way to know what is in them or how pure they are. Do not inject any product that is not prescribed to you and dispensed by a licensed pharmacy. Our guide on how to spot counterfeit medicines explains the warning signs.
Approved Options You Can Use Now
If you need help with weight or type 2 diabetes today, approved medicines are available with a prescription while the amylin drugs finish testing. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved weight management medicines, and Mounjaro (tirzepatide) is approved for type 2 diabetes.
Wegovy
Semaglutide
Approved weight management medicine
You can order Wegovy through Pharma Giant, which fills U.S. prescriptions with licensed Canadian pharmacies.
Shop Wegovy How much Wegovy costs without insuranceZepbound
Tirzepatide
Approved weight management medicine
Available through Pharma Giant with a valid prescription.
Shop Zepbound How much Zepbound costs without insuranceMounjaro
Tirzepatide
Approved for type 2 diabetes
Available through Pharma Giant with a valid prescription.
Shop Mounjaro How much Mounjaro costsNot sure which weight loss option fits? Read our Zepbound vs Wegovy comparison.
Whichever medicine you use, get it from a licensed pharmacy, take it exactly as prescribed, and talk with your prescriber before starting, stopping or switching treatment.




